OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Immunology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Antigen discovery for the development of cancer immunotherapy	132
The role of ILC subsets in cancer	111
Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy	98
DNGR-1-mediated cross-presentation of dead cell-associated antigens	82
Systems biology of B cells in COVID-19	70
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells	66
Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases	60
Immune responses to SARS-CoV-2 infection and vaccination in children	57
Introduction to the Special Issue: Immuno-oncology	50
Editorial Board	50
Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS	46
Durability of immune responses to SARS-CoV-2 infection and vaccination	44
Editorial Board	43
Connecting the dots: Neutrophils at the interface of tissue regeneration and cancer	39
Genetics of Inborn Errors of Immunity in highly consanguineous Middle Eastern and North African populations	37
Systems analysis of innate and adaptive immunity in Long COVID	36
B cells and the intestinal microbiome in time, space and place	35
Multidimensional molecular controls defining NK/ILC1 identity in cancers	35
G-CSF, the guardian of granulopoiesis	33
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities	32
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel	32
Accumulation of immune-suppressive CD4 + T cells in aging – tempering inflammaging at the expense of immunity	32
Toolkit for mapping the clonal landscape of tumor-infiltrating B cells	32
Thymus aging and immune reconstitution, progresses and challenges	31
Immunomodulatory effects of G-CSF in cancer: Therapeutic implications	30

Versatile neutrophil functions in cancer	29
Exploiting antifungal immunity in the clinical context	29
IL-33: A central cytokine in helminth infections	28
Cellular and Molecular Diversity in Scleroderma	27
Harnessing TH9 cells in cancer immunotherapy	27
The origins, manifestations, and potential treatments of allergic disorders	26
High-throughput N-glycan analysis in aging and inflammaging: State of the art and future directions	26
Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients	26
Sialic acid and Siglec receptors in tumor immunity and immunotherapy	26
Microbial gasdermins: More than a billion years of pyroptotic-like cell death	25
Resolution pharmacology − A fresh approach to the clinical management of human inflammatory diseases	25
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls	24
Nanoparticles for generating antigen-specific T cells for immunotherapy	24
IL-1R8: A molecular brake of anti-tumor and anti-viral activity of NK cells and ILC	24
Recent developments in C3-targeted complement therapeutics	22
T cell immunity to SARS-CoV-2	22
The role of unconventional T cells in maintaining tissue homeostasis	21
Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair	21
Formyl peptide receptor 2 and heart disease	21
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology	21
The neglected brothers come of age: B cells and cancer	20
Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond	19
Pyroptosis-induced inflammation and tissue damage	19
Integrating immunopeptidome analysis for the design and development of cancer vaccines	19
Immune aging – A mechanism in autoimmune disease	19
Reparative inflammation in multiple sclerosis	19
The dual role of neutrophils in cancer	19
Inflammasomes as regulators of non-infectious disease	18
NGS data analysis for molecular diagnosis of Inborn Errors of Immunity	18
The impact of immunopeptidomics: From basic research to clinical implementation	18
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion	17
Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet	17
Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example	16
Pyroptosis modulation by bacterial effector proteins	15
The gut mucus network: A dynamic liaison between microbes and the immune system	15
Editorial Board	14
The tissue glycome as regulator of immune activation and tolerance mediated by C-type lectins and Siglecs	14
Natural killer cells and type 1 innate lymphoid cells in cancer	13
Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives	13
Introduction to the Special Issue: The Immunopeptidome	13
Colony stimulating factors in the nervous system	13
Introduction to the special issue: Cellular and molecular diversity in rheumatic autoimmune diseases	13
Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases	13
Current insights in mouse iNKT and MAIT cell development using single cell transcriptomics data	13
Immunomodulatory and immunoregulatory nanomedicines for autoimmunity	13
Contemplating immunopeptidomes to better predict them	13
Introduction to the Special Issue: Nutrition, microbiota and immunity	13
They shall not grow mold: Soldiers of innate and adaptive immunity to fungi	12
Aging of lymphoid stromal architecture impacts immune responses	12
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing	12

The immunology and cell biology of T cell aging	12
Checkpoint blockade toxicities: Insights into autoimmunity and treatment	12
Empowering patients from within: Emerging nanomedicines for in vivo immune cell reprogramming	12
Pathways of MHC I cross-presentation of exogenous antigens	11
Age-dependent changes in T follicular helper cells shape the humoral immune response to vaccination	11
Microbial metabolites and immunotherapy: Basic rationale and clinical indications	11
T cell control of SARS-CoV-2: When, which, and where?	11
Resolving inflammatory links between myocardial infarction and vascular dementia	11
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease	11
Enteric neuro-immune interactions in intestinal health and disease	11
The world’s largest experiment in human immunology	11
Nanobodies in cancer	11
E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinic	11
Development of γδ T cells in the thymus – A human perspective	11
What fungal CNS infections can teach us about neuroimmunology and CNS-specific immunity	10
The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens	10
Non-coding RNA-based regulation of inflammation	10
Introduction to the special issue: Complexity and diversity of immune responses in COVID-19	10
Editorial Board	10
Targeting the tissue-complosome for curbing inflammatory disease	10
Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases	10
Emerging concepts in PD-1 checkpoint biology	10
Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond	10
Emerging features of MAIT cells and other unconventional T cell populations in human viral disease and vaccination.	10
Neutrophil metabolism in the cancer context	10
Remote regulation of type 2 immunity by intestinal parasites	9
Immunoglobulins at the interface of the gut mycobiota and anti-fungal immunity	9
T cell control of inflammaging	9
Immunity to pathogenic fungi in the eye	9
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?	9
T cell fate decisions during memory cell generation with aging	8
The biogenesis of the immunopeptidome	8
Tumor resident regulatory T cells	8
Redefining microglia states: Lessons and limits of human and mouse models to study microglia states in neurodegenerative diseases	8
Complexity of immune responses in COVID-19	8
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity	8
Polyvalent design in the cGAS-STING pathway	8
Contributions of the early-life microbiome to childhood atopy and asthma development	8
Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7)	8
Innovations in lymph node targeting nanocarriers	7
IL-34, the rationale for its expression in physiological and pathological conditions	7
Numbers and odds: TCR repertoire size and its age changes impacting on T cell functions	7
Pyroptosis in cardiovascular diseases: Pumping gasdermin on the fire	7
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy	7
Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?	7
Nanoalum adjuvanted vaccines: small details make a big difference	7
Introduction to the Special Issue: Pyroptosis in Immunity and Inflammation	7
Regulatory T cells in allergic inflammation	7
Shaping hematopoietic cell ecosystems through galectin-glycan interactions	7